Cervical cancer begins in the cells of the cervix—the lower part of the uterus that connects to the vagina. Nearly all cases are caused by persistent infections with high-risk strains of the human papillomavirus (HPV), a virus transmitted through intimate contact. While rates in the U.S. have dropped in recent decades, 13,820 individuals were diagnosed in 2024, and more than 4,360 lives were lost. These numbers highlight the importance of prevention and early detection.
Prevention: HPV Vaccines and Routine Screening
Cervical cancer is one of the most preventable cancers. The HPV vaccine, such as Gardasil 9, offers protection against nine high-risk strains of HPV and is recommended for individuals aged 9 to 45, with the first dose ideally given at age 11 or 12. Research shows that among women aged 20 to 24—those most likely to have received the vaccine—cervical cancer rates decreased by 65% from 2012 to 2019.
Screening tests like the Pap smear and HPV test are equally essential. These tools detect precancerous changes or high-risk HPV infections early, when treatment is most effective. Guidelines suggest Pap tests every three years starting at age 21 and combined screening every five years for those aged 30 to 65.
The Oncology Institute’s Dedication to Cervical Cancer Care
At The Oncology Institute, we are dedicated to providing comprehensive care and educating our community about cervical cancer prevention. By offering resources and access to preventative tools like vaccines and screenings, we strive to reduce the impact of this disease.
Take the first step—schedule your screening or ask your healthcare provider about the HPV vaccine. Learn more about cervical cancer prevention and treatment by visiting the AACR’s resource page (https://www.aacr.org/
Together, we can make progress toward eliminating cervical cancer for future generations.
